Transmission-Blocking Vaccine Pvs230D1-EPA/Matrix-M in Healthy Malaria-Naive Adults Using a Plasmodium Vivax Controlled Human Malaria Infection and Transmission Model
Open the official record
This page only displays public information reproduced from the official ClinicalTrials.gov record NCT07930585. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 1/2 Study of Transmission-Blocking Vaccine Pvs230D1-EPA/Matrix-M in Healthy Malaria-Naive Adults Using a Plasmodium Vivax Controlled Human Malaria Infection and Transmission Model
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Background: Malaria is a disease caused by parasites spread by mosquito bites. Researchers want to test a vaccine that could stop mosquitoes from picking up these parasites when they bite infected people. This could stop malaria from spreading. Objective: To test a study vaccine (Pvs230D1-EPA/MM) to stop malaria transmission in healthy adults. Eligibility: Healthy people aged 18 to 54 years. People who already received the vaccine during a different study are also needed. Design: Participants will be screened. They will have a physical exam. They will have blood tests and a test of their heart function (a simple electrocardiogram or EKG). The vaccine is given as an injectionin the upper arm. Participants who have never gotten the study vaccine will get 3 vaccines; each injection will be about 1 month apart. Participants who were vaccinated before will receive only 1 vaccine for this study. All participants will have multiple phone and in-person follow-up visits after each vaccination. Two to 12 weeks after their last vaccine, all participants will be injected with live malaria parasites. Then they will be seenin the clinic for about 3 days. They will be monitored daily until they develop symptoms of malaria, usually in about 10 days then will be admitted to the NIH hospital. While in the NIH hospital, participants will have 3 mosquito feedings: Two cups containing mosquitoes will be placed on an arm or leg. The mosquitoes will feed for about 15 minutes. Participants will receive medicines to relieve discomfort from the bites. Participants will then be treated for malaria. They will have follow-up visits and calls until they fully recover.
Study identification
- NCT ID
- NCT07930585
- Recruitment status
- Not yet recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 220 participants
Conditions and interventions
Conditions
Interventions
- Plasmodium vivax Challenge Agent Derived from PvHMB-CCE001 Biological
- Pvs230D1-EPA/Matrix-M Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years to 54 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 18, 2026 (Estimated)
- Primary completion
- Nov 1, 2029 (Estimated)
- Completion
- Nov 1, 2029 (Estimated)
- Last update posted
- Nov 13, 2026
2026 – 2029
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| National Institutes of Health Clinical Center | Bethesda | Maryland | 20892 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07930585, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 13, 2026 · Synced Nov 15, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.